Coronavirus | CFTRI to sequence SARS-CoV-2 genome

Signs MoU with Bengaluru company

December 08, 2020 09:37 pm | Updated 11:24 pm IST - MYSURU

Photo: cftri.res.in/

Photo: cftri.res.in/

As part of various initiatives towards mitigating COVID-19, CSIR-Central Food Technological Research Institute (CFTRI) signed an MoU with Clevergene, a Bengaluru-based company, for sequencing the SARS-CoV-2 genome.

It is expected that the study would provide insights into the virus’s genome changes (mutations), evolution, epidemiology, and provide an understanding of the spatial and temporal information on infection dynamics of the SARS-CoV-2.

Under the MoU, the development of novel diagnostics and vaccines for COVID-19 are envisaged, according to the institute. CSIR-CFTRI has established a COVID-19 Testing Centre in Mysuru and an average of 1,000 samples are tested daily.

CFTRI is also working on the development of novel dipstick and aptamer-based diagnostics in collaboration with private parties. Clevergene is a technology company offering genomics services for contract research and genetic diagnostics, a release said here.

The MoU was exchanged between B. Manohar, Chief Scientist and Adviser (M and A), and Tony Jose, Co-Founder, and CEO, Clevergene.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.